Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
20 06 2023
Historique:
medline: 22 6 2023
pubmed: 20 6 2023
entrez: 20 6 2023
Statut: ppublish

Résumé

Major depressive disorder (MDD), a common mental disorder in the US, may have substantial impact on the lives of affected individuals. If left untreated, MDD can interfere with daily functioning and can also be associated with an increased risk of cardiovascular events, exacerbation of comorbid conditions, or increased mortality. The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate benefits and harms of screening, accuracy of screening, and benefits and harms of treatment of MDD and suicide risk in asymptomatic adults that would be applicable to primary care settings. Asymptomatic adults 19 years or older, including pregnant and postpartum persons. Older adults are defined as those 65 years or older. The USPSTF concludes with moderate certainty that screening for MDD in adults, including pregnant and postpartum persons and older adults, has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on the benefit and harms of screening for suicide risk in adults, including pregnant and postpartum persons and older adults. The USPSTF recommends screening for depression in the adult population, including pregnant and postpartum persons and older adults. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in the adult population, including pregnant and postpartum persons and older adults. (I statement).

Identifiants

pubmed: 37338872
pii: 2806144
doi: 10.1001/jama.2023.9297
doi:

Types de publication

Journal Article Practice Guideline Research Support, U.S. Gov't, P.H.S. Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2057-2067

Commentaires et corrections

Type : SummaryForPatientsIn
Type : CommentIn

Auteurs

Michael J Barry (MJ)

Harvard Medical School, Boston, Massachusetts.

Wanda K Nicholson (WK)

George Washington University, Washington, DC.

Michael Silverstein (M)

Brown University, Providence, Rhode Island.

David Chelmow (D)

Virginia Commonwealth University, Richmond.

Tumaini Rucker Coker (TR)

University of Washington, Seattle.

Karina W Davidson (KW)

Feinstein Institutes for Medical Research at Northwell Health, Manhasset, New York.

Esa M Davis (EM)

University of Pittsburgh, Pittsburgh, Pennsylvania.

Katrina E Donahue (KE)

University of North Carolina at Chapel Hill.

Carlos Roberto Jaén (CR)

The University of Texas Health Science Center, San Antonio.

Li Li (L)

University of Virginia, Charlottesville.

Gbenga Ogedegbe (G)

New York University, New York, New York.

Lori Pbert (L)

University of Massachusetts Medical School, Worcester.

Goutham Rao (G)

Case Western Reserve University, Cleveland, Ohio.

John M Ruiz (JM)

University of Arizona, Tucson.

James J Stevermer (JJ)

University of Missouri, Columbia.

Joel Tsevat (J)

The University of Texas Health Science Center, San Antonio.

Sandra Millon Underwood (SM)

University of Wisconsin, Milwaukee.

John B Wong (JB)

Tufts University School of Medicine, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH